drugset / Trial / NCT05290220
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is conducted in patients with advanced hepatocellular carcinoma (HCC). This study includes three arms: A, B, and C. Arm A will receive HLX07 combination therapy with HLX10 and HLX04 as first line treatment. Arm B will receive HLX07 combination therapy with lenvatinib as second line treatment. Arm C will receive HLX07 monotherapy as third-line or above treatment. All of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent (whichever occurs first, HLX10 treatment up to 2 years).
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-12-15
- Completion
- 2024-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | PIMURUTAMAB | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |